Suspended

A Phase II Randomized Trial With Captopril In Patients Who Have Received Radiation Therapy +/- Chemotherapy For Stage II-IIIB Non-Small Cell Lung Cancer, Stage I Central Non-Small Cell Lung Cancer, Or Limited-Stage Small-Cell Lung Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

captopril

Drug
Who is being recruted

Radiation Fibrosis Syndrome
+13

+ Bronchial Neoplasms
+ Carcinoma, Bronchogenic
Over 18 Years
See all eligibility criteria
How is the trial designed

Supportive Care Study

Phase 2
Interventional
Study Start: June 2003
See protocol details

Summary

Principal SponsorRadiation Therapy Oncology Group
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: June 1, 2003Actual date on which the first participant was enrolled.

OBJECTIVES: * Determine the effect of captopril on the incidence of pulmonary damage at 12 months after radiotherapy with or without chemotherapy in patients with stage II-IIIB non-small cell lung cancer, stage I central non-small cell lung cancer, or limited stage small cell lung cancer. * Compare the quality of life of patients treated with captopril vs patients who undergo post-radiotherapy observation only. * Determine the persistence of captopril's effect on pulmonary toxicity in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, total lung irradiated (< 25% vs 25-37% vs more than 37%), prior surgery (yes vs no), and prior chemotherapy (yes vs no). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral captopril 3 times daily for 1 year in the absence of disease progression or unacceptable toxicity. * Arm II: Patients undergo observation only for 1 year. Quality of life is assessed at baseline and at months 3, 6, 12, and 18. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 205 patients will be accrued for this study within 18 months.

Official TitleA Phase II Randomized Trial With Captopril In Patients Who Have Received Radiation Therapy +/- Chemotherapy For Stage II-IIIB Non-Small Cell Lung Cancer, Stage I Central Non-Small Cell Lung Cancer, Or Limited-Stage Small-Cell Lung Cancer 
NCT00077064
Principal SponsorRadiation Therapy Oncology Group
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
81 patients to be enrolledTotal number of participants that the clinical trial aims to recruit.
Supportive Care Study
These studies explore ways to improve comfort and daily life for people living with a condition. They may focus on easing symptoms, reducing treatment side effects, or supporting overall well-being.

How participants are assigned to different groups/arms
In this clinical study, participants are placed into groups randomly, like flipping a coin. This ensures that the study is fair and unbiased, making the results more reliable. By assigning participants by chance, researchers can better compare treatments without external influences.

Other Ways to Assign Participants
Non-randomized allocation
: Participants are assigned based on specific factors, such as their medical condition or a doctor's decision.

None (Single-arm trial)
: If the study has only one group, all participants receive the same treatment, and no allocation is needed.

How treatments are given to participants
Participants are divided into different groups, each receiving a specific treatment at the same time. This helps researchers compare how well different treatments work against each other.

Other Ways to Assign Treatments
Single-group assignment
: Everyone gets the same treatment.

Cross-over assignment
: Participants switch between treatments during the study.

Factorial assignment
: Participants receive different combinations of treatments.

Sequential assignment
: Participants receive treatments one after another in a specific order, possibly based on individual responses.

Other assignment
: Treatment assignment does not follow a standard or predefined design.

How the effectiveness of the treatment is controlled
In a non placebo-controlled study, no participants receive an inert substance (placebo) to compare outcomes. Instead, all participants receive either the experimental treatment or an alternative treatment (often the Standard of Care). This method allows researchers to compare the effects of the experimental treatment with those of a different active intervention, rather than a placebo.

Other Options
Placebo-Controlled
: A placebo is used to compare the effects of the experimental treatment with those of an inert substance, isolating the true treatment effect.

How the interventions assigned to participants is kept confidential
Everyone involved in the study knows which treatment is being given. This is typically used when it's not possible or necessary to hide the treatment details from participants or researchers.

Other Ways to Mask Information
Single-blind
: Participants do not know which treatment they are receiving, but researchers do.

Double-blind
: Neither participants nor researchers know which treatment is given.

Triple-blind
: Participants, researchers, and outcome assessors do not know which treatment is given.

Quadruple-blind
: Participants, researchers, outcome assessors, and care providers all do not know which treatment is given.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
Over 18 YearsRange of ages for which participants are eligible to join.
Healthy volunteers not allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Radiation Fibrosis Syndrome
Bronchial Neoplasms
Carcinoma, Bronchogenic
Carcinoma, Non-Small-Cell Lung
Fibrosis
Lung Diseases
Lung Neoplasms
Neoplasms
Neoplasms by Site
Pathologic Processes
Radiation Injuries
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Wounds and Injuries
Small Cell Lung Carcinoma
Criteria

DISEASE CHARACTERISTICS: * One of the following histologically or cytologically confirmed diagnoses: * Stage II-IIIB non-small cell lung cancer (NSCLC) * Stage I central NSCLC * No peripheral coin lesions * Limited stage small cell lung cancer * Nonmetastatic disease that is receiving radiotherapy and the target is confined to a single radiotherapy treatment area * Planning to receive radiotherapy * At least 45 Gy to be delivered to the target volume * More than 25% of total lung volume to receive \> 20 Gy if receiving radiotherapy alone PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Zubrod 0-1 Hematopoietic * Absolute granulocyte count greater than 1,000/mm\^3 * Platelet count greater than 75,000/mm\^3 * Hemoglobin greater than 9.0 g/dL (transfusion allowed) Hepatic * Bilirubin less than 1.5 mg/dL * Serum glutamate oxaloacetate transaminase (SGOT) less than 2 times normal Renal * Blood urea nitrogen (BUN) less than 25 mg/dL * Creatinine less than 1.6 mg/dL * Urine protein less than 10 mg/dL * Urine glucose negative Cardiovascular * Systolic blood pressure greater than 110 mm Hg * Diastolic blood pressure greater than 60 mm Hg Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Sodium normal * Potassium normal * No collagen vascular disease (e.g., lupus or scleroderma) * Rheumatoid arthritis allowed * No known hypersensitivity to ACE inhibitors PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Induction or concurrent chemotherapy allowed either during radiotherapy or during therapy with captopril * No concurrent methotrexate Endocrine therapy * Not specified Radiotherapy * See Disease Characteristics Surgery * Prior pulmonary lobectomy or segmentectomy allowed * No prior pneumonectomy Other * No concurrent angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor antagonists for hypertension or congestive heart failure * No concurrent lithium * No concurrent procainamide


Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives
One single intervention group 

is designated in this study

This study does not include a placebo group 

Treatment Groups
Group I
Experimental
Captopril

Captopril 12.5 mg t.i.d. for first two weeks, increased to 25 mg t.i.d. for the second two weeks of therapy. Thereafter, the dose will be increased to 50 mg t.i.d. for the remainder of the one-year of therapy (52 total weeks of drug administration).
Study Objectives
Primary Objectives

Incidence of Grade 2+ radiation-induced pulmonary toxicity within 1 year after completion of radiation. Assuming that the incidence of pulmonary toxicity would be 50%, based on Fisher's exact test with a one-sided significance level of 0.05,168 randomized patients would be required to have 80% statistical power to detect a 40% relative reduction (from 50% to 30%) in the incidence of pulmonary toxicity while receiving captopril. Assuming that 15% of cases would not continue to the randomization stage and 5% of patients would be found ineligible, the target sample size was 205 patients. Given the actual sample size, power would be 25% and therefore p-values were not reported.
Secondary Objectives

Biomarker data will not be generated from these tissue specimens, therefore this analysis will not take place.

Only 2 patients have the required data- only 1.2% of the planned enrollment and 2.5% of the actual enrollment- which is extremely problematic as this data cannot be generalized, leads to selection bias, and is not representative of the patient population. Therefore the analysis was not conducted.

Patients who experienced a Grade 2+ radiation-induced pulmonary toxicity within 1 year after completion of radiation were assessed to determine if the toxicity persisted for 2 years.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 87 locations
Suspended
Lurleen Wallace Comprehensive Cancer at University of Alabama - BirminghamBirmingham, United StatesSee the location
Suspended
Mobile Infirmary Medical CenterMobile, United States
Suspended
Arizona Oncology Services FoundationPhoenix, United States
Suspended
Providence Saint Joseph Medical Center - BurbankBurbank, United States

Suspended87 Study Centers
;